Clinical Trials on Recurrent Skin Squamous Cell Carcinoma

Total 17765 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma

United States
Alpha Tau Medical LTD.

Recruiting

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recurrent Squamous Cell Carcinoma

United States, Israel
Hyunseok Kang, MD
NeoImmuneTech

Recruiting

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Recurrent Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma | Stage I Skin Cancer | Stage II Skin Cancer | Stage III Skin Cancer

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
Stanford University
National Cancer Institute (NCI)

Terminated

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
Regeneron Pharmaceuticals
Sanofi

Completed

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Recurrent Squamous Cell Carcinoma of Head | Recurrent Squamous Cell Carcinoma of Neck | Metastatic Squamous Cell Carcinoma of Head | Metastatic Squamous Cell Carcinoma Neck

Korea, Republic of, United Kingdom
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditions

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Squamous Cell Carcinoma of the...

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell Carcinoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditions

Canada, United States
Emory University
National Cancer Institute (NCI)

Recruiting

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Locally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal...
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Active, not recruiting

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Recurrent Skin Carcinoma | Skin Squamous Cell Carcinoma

United States
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); The Cleveland Clinic; National... and other collaborators

Active, not recruiting

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma

United States
University of Malaya
Merck Sharp & Dohme LLC; Cancer Research Malaysia; National Cancer Institute,... and other collaborators

Recruiting

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) (PIPER)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Malaysia
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell... and other conditions

United States
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia
M.D. Anderson Cancer Center

Recruiting

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
University College, London
Merck Sharp & Dohme LLC

Recruiting

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United Kingdom
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC; Joseph Sanchez Foundation

Active, not recruiting

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center

Withdrawn

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)

Active, not recruiting

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
NATCO Pharma Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Carcinoma | Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

United States, India
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC (ELANFIT)

Metastatic or Recurrent Head and Neck Squamous Cell Cancer

France
Glenn J. Hanna
ImmunityBio, Inc.

Recruiting

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Carcinoma

United States
Vanderbilt-Ingram Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Withdrawn

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head or Neck | Metastatic Squamous Cell Carcinoma of the Head or Neck
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in... and other conditions

Canada
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Shyam S.D. Rao
National Cancer Institute (NCI)

Recruiting

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Metastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer | Recurrent Head and Neck Squamous Cell Cancer | Metastatic Head and Neck Squamous Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma

United States
Replimune Inc.
Bristol-Myers Squibb

Withdrawn

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Squamous Cell Carcinoma of Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, United Kingdom, Czechia, France, Germany, Greece, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Second Primary Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States

Clinical Trials on Recurrent Skin Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations